Bafna Pharmaceuticals Limited (BAFNAPH) Stock Statistics & Valuation Metrics

Bafna Pharmaceuticals Limited has a market cap or net worth of ₹6.54B. The enterprise value is ₹3.03K.

Bafna Pharmaceuticals Limited has 23,656,336 shares outstanding. The number of shares has decreased by -2.65% in one year.

Bafna Pharmaceuticals Limited’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 7.16%.

The current PE Ratio of Bafna Pharmaceuticals Limited is 88.5. Bafna Pharmaceuticals Limited’s PEG ratio is 0.14.

In the last 12 months, Bafna Pharmaceuticals Limited had revenue of 1.51B and earned 111.00M in profits. Earnings per share was 4.69.

In the last 12 months, operating cash flow was 93.13M and capital expenditures -164.17M, giving a free cash flow of -71.04M billion.

Bafna Pharmaceuticals Limited pays an annual dividend of ₹0.6, resulting in a dividend yield of ―

Bafna Pharmaceuticals Limited upcoming earnings date is Nov 12, 2026, TBA (Confirmed).

Bafna Pharmaceuticals Limited as a current ratio of 1.57, with Debt / Equity ratio of 38.93%

In the past 12 months, Bafna Pharmaceuticals Limited has paid -1.30M in taxes.

Bafna Pharmaceuticals Limited EV to EBITDA ratio is 14.21, with an EV/FCF ratio of -22.50.

Bafna Pharmaceuticals Limited has ₹20.25M in cash and marketable securities with ₹374.33M in debt, giving a net cash position of -₹354.09M billion.

Gross margin is 22.77%, with operating margin of 6.56%, and net profit margin of 7.37%.

The average price target for Bafna Pharmaceuticals Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―